Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, with a total limit of up to RMB 2.5 billion, ensuring the normal operation of investment projects and fund safety [2]. Group 1: Fund Management Approval - The company held the eighth board meeting and the eighth supervisory board meeting on January 20, 2025, where it approved the use of idle raised funds not exceeding RMB 1.0 billion and idle self-owned funds not exceeding RMB 1.5 billion for cash management and entrusted financial management [2][3]. - The investment products chosen are characterized by high safety, good liquidity, and a maturity period not exceeding 12 months [2]. Group 2: Redemption of Financial Products - Recently, the company and its wholly-owned subsidiaries have redeemed all principal and income from cash management and entrusted financial products [2][6]. - The company has disclosed detailed information regarding the redemption of these financial products in various announcements [2]. Group 3: Approval Process - The proposal for using idle funds for cash management was approved by both the board of directors and the supervisory board, with clear consent from the supervisory board and the sponsor institution [3]. Group 4: Financial Impact - As of the announcement date, the company has no outstanding balance of idle raised funds for cash management, and the total usage of self-owned funds for cash management and entrusted financial management is also zero, remaining within the authorized limits set by the board [6].
吉林省西点药业科技发展股份有限公司关于使用闲置募集资金及自有资金进行现金管理和委托理财到期赎回的公告